BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has announced that monthly US sales of its flagship VINIA product surpassed $1 million in August 2023.
The company said in a statement that the “significant milestone” marks a new inflection point in its journey and further validates its Botanical Synthesis technology platform.
"What makes this milestone so outstanding is that it is being achieved while improving marketing efficiency,” CEO Ilan Sobel commented in a statement.
“This gives us a strong shot of confidence in the future to come, as we prepare to bring additional products to market.”
BioHarvest also noted that VINIA continues to achieve a best-in-class verified customer rating of 4.8 out of 5 with over 2,700 verified reviews.
With production capacity on the ascending curve, it said it plans to leverage the sales momentum in order to reach the efficiencies of scale required to achieve profitability in the near term.
“We have built a powerful direct marketing and sales platform already capable of delivering over $1 million in monthly revenue with just one product SKU,” Sobel added.
“I am looking forward to reaching new revenue milestones as we aggressively grow our product portfolio in the next 12 months."
BioHarvest is a biotechnology firm that has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruits and plants at an industrial scale without needing to grow the plant itself.
Contact the author at stephen.gunnion@proactiveinvestors.com